Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 7%. The IND application for CS5007, which is expected to become the Hong Kong Stock Exchange Standard, was approved by the China NMPA

Zhitongcaijing · 4d ago

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose more than 7%. As of press release, it had risen 6.94% to HK$5.92, with a turnover of HK$24.531 million.

According to the news, recently, Hang Seng Index Company announced the results of the Hang Seng Index series quarterly review results up to June 30, 2026. Among them, Cornerstone Pharmaceutical-B was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Cornerstone Pharmaceutical-B may be transferred to the Hong Kong Stock Connect because it meets a range of standards including market value and liquidity.

It is worth noting that Cornerstone Pharmaceutical-B announced that the new drug clinical trial application (IND) of CS5007 (EGFR/HER3 bispecific antibody conjugate drug [ADC]), one of the core drug candidates in the company's pipeline 2.0, was quickly approved through the China National Drug Administration (NMPA) innovative drug clinical trial review and approval channel, and the whole process took only 23 working days. Previously, the global multi-center phase I clinical trial of CS5007 was initiated in Australia in June 2026 and the first patient enrollment was completed. The trial will also be carried out simultaneously in China.